Non-Small-Cell Lung Cancer Clinical Trial
Official title:
A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL999 Administered Intravenously to Subjects With Non-Small-Cell Lung Cancer (NSCLC)
Verified date | February 2010 |
Source | Symphony Evolution, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to determine the safest dose of XL999 and how well subjects with Non-Small-Cell Lung Cancer tolerate XL999. XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.
Status | Terminated |
Enrollment | 2 |
Est. completion date | May 2008 |
Est. primary completion date | January 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. The subject has a confirmed histological diagnosis of NSCLC. 2. The subject has previously been treated with a platinum- or taxane-containing regimen. 3. The subject has stage IIIB NSCLC with malignant effusion, stage IV or recurrent NSCLC that is not amenable to curative therapy (either surgery or radiation therapy). 4. The subject is at least 18 years old. 5. The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of =2. 6. The subject has a life expectancy of =3 months. 7. The subject has adequate organ and marrow function. 8. The subject has cardiac-specific enzyme levels (creatine phosphokinase [CPK] total, CPK-MB, and troponin) below the institution's ULN. 9. The subject is capable of understanding the protocol and has signed the informed consent document. 10. Sexually active subjects (male and female) must use medically accepted methods of contraception during the entire course of the study. 11. Female subjects of childbearing potential must have a negative pregnancy test at enrollment. 12. If a subject has received more than three prior regimens of cytotoxic chemotherapy, or more than two biological or targeted therapies, or more than 3000 cGy to >25% of his or her bone marrow, the investigator must discuss with the sponsor regarding subject suitability prior to enrollment. 13. The subject has had no other diagnosis of malignancy (unless non-melanoma skin cancer, in situ carcinoma of the cervix, or a malignancy diagnosed =5 years ago, and has had no evidence of disease for 5 years prior to screening for this study). Exclusion Criteria: 1. The subject has received systemic anticancer therapy (eg, chemotherapy, biologic therapy, targeted therapy, cytokines, or hormones) within 14 days before the first dose of study drug. 2. The subject has received radiation to >25% of his or her bone marrow within 30 days of XL999 treatment. 3. The subject has not recovered to Grade =1 from adverse events (AEs) due to investigational or other agents administered more than 14 days prior to study enrollment. 4. The subject has history of or known brain metastases, current spinal cord compression, or carcinomatous meningitis. 5. The subject is known to be positive for the human immunodeficiency virus (HIV). 6. The subject has uncontrolled and/or intercurrent illness including but not limited to the following: 1. Cardiac: - Left ventricular ejection fraction (LVEF) assessed by 99mTc multiple-gated acquisition scan (MUGA) is below the institution's lower limit of normal (LLN) at screening. If regional wall motion abnormalities are noted on the MUGA, cardiology consultation should be performed prior to enrollment. - History of pulmonary hypertension. - History of congestive heart failure (CHF) (New York Heart Association [NYHA] Class II, III, or IV). - Active or unstable ischemic disease, including angina pectoris, myocardial infarction, coronary artery bypass grafting (CABG) within the past 12 months. - Electrocardiogram (ECG) showing signs of ischemia or myocardial, valvular, or coronary artery disease unless deemed clinically insignificant by a cardiologist. - Onset of any changes between the screening ECG and pre-dose ECG unless deemed clinically insignificant by a cardiologist. - ECG abnormalities that could cause interpretation difficulties after XL999 administration (eg, left bundle branch block [LBBB], atrial fibrillation, A-V blocks, pacemakers, digoxin). 2. Vascular: - Blood pressure >150/90 mm Hg despite antihypertensive therapy with two medications. - Cerebrovascular accident, transient ischemic attack, or evidence of active peripheral vascular disease within 12 months prior to study enrollment. 3. Hematologic: - National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0 Grade =3 hemorrhage within 30 days of study enrollment. - Evidence of bleeding diathesis or coagulopathy. - Requirement for therapeutic anticoagulation. Patients receiving anticoagulants (eg, warfarin, heparin) will be excluded if international normalized ratio >1.5 or partial thromboplastin time (PTT) >1.5× the institution's ULN. 4. Recent surgical procedures: - Major surgery or open biopsy within 30 days of starting treatment with XL999. - Anticipation of major surgical procedure during the study. 5. Wound healing problems: - History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 30 days prior to treatment. - Serious, non-healing wound, ulcer, or bone fracture. 6. Psychiatric illness that would limit compliance with study requirements. 7. The subject is pregnant or breastfeeding. 8. The subject has a known allergy or hypersensitivity to components of the XL999 formulation. 9. The subject is unable or unwilling to abide by the study. |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Peachtree Hematology Oncology Consultants | Atlanta | Georgia |
United States | Wayne State University, Karmanos Cancer Institute | Detroit | Michigan |
United States | UCLA Medical Center | Los Angeles | California |
United States | Hematology-Oncology Associates of Rockland | Nyack | New York |
United States | Cancer Therapy and Research Center at The UT Health Science Center at San Antonio | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
Symphony Evolution, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety, tolerability, and maximum tolerated dose of XL999 administered weekly as a 4-hour intravenous infusion | Inclusion until 30 days post last treatment | Yes | |
Secondary | Plasma pharmacokinetics of XL999 administered weekly as a 4-hour intravenous infusion | At various time points during the 4 week Treatment Period and the Treatment Extension Period | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02495233 -
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02672358 -
Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC
|
Phase 2 | |
Recruiting |
NCT05815472 -
Advanced Patient Monitoring and A.I. Supported Outcomes Assessment in Lung Cancer Using Internet of Things Technologies (A.I. - APALITT)
|
N/A | |
Not yet recruiting |
NCT05900219 -
Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study
|
Phase 2 | |
Not yet recruiting |
NCT04560244 -
A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment
|
Phase 2 | |
Not yet recruiting |
NCT02907606 -
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
|
N/A | |
Completed |
NCT01924416 -
Lung Cancer Information Study (LCIS-R01)
|
N/A | |
Completed |
NCT01136083 -
Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients
|
N/A | |
Completed |
NCT00831454 -
Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection
|
N/A | |
Completed |
NCT00363766 -
Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00913705 -
Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer
|
Phase 3 | |
Completed |
NCT01124864 -
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.
|
Phase 2 | |
Completed |
NCT01383135 -
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
|
Early Phase 1 | |
Completed |
NCT00049998 -
Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer
|
Phase 3 | |
Terminated |
NCT05061537 -
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT03320044 -
Early Diagnosis of Small Pulmonary Nodules by Multi-omics Sequencing
|
||
Recruiting |
NCT04895930 -
Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
|
Phase 2 | |
Recruiting |
NCT03267654 -
Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance
|
Phase 2 | |
Recruiting |
NCT04401059 -
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective Study
|
Phase 4 | |
Completed |
NCT02965391 -
Dynamic Changes of Circulating Tumor DNA in Surgical Lung Cancer Patients
|